Iguratimod suppresses Tfh cell differentiation in primary Sjogren's syndrome patients through inhibiting Akt/mTOR/STAT3 signaling.

ABSTRACT:

Background

Iguratimod (IGU) reduces hypergammaglobulinemia and disease activity in pSS (primary Sjögren's syndrome) patients. However, the therapeutical mechanism of IGU for pSS remains largely unknown. This study aimed to investigate the regulation of Tfh cell differentiation by IGU in pSS patients.

Methods

We prospectively enrolled 13 pSS patients treated with IGU for 3 months and examined circulating T cell and B cell subsets by flow cytometry. We measured Tfh cell differentiation treated by IGU in pSS patients and healthy controls. Transcriptome analysis combined with molecular docking were employed to identify potential therapeutical targets of IGU, which were verified by Western blot and Tfh cell differentiation.

Results

Tfh, plasmablast, and plasma cells were s

SUBMITTER: Lyu T 

PROVIDER: S-EPMC10463648 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature